Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indaptus Therapeutics, Inc. (Nasdaq: INDP) SEC filings page on Stock Titan provides structured access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer incorporated in Delaware and listed on the Nasdaq Capital Market, Indaptus uses its SEC reports to describe the development of its Decoy bacterial immunotherapy platform, its clinical programs, and its financing and corporate activities.
Through Forms 10-K and 10-Q, investors can review detailed discussions of Indaptus’ business, including its focus on Decoy20 and related product candidates for cancer and viral infections, pre-clinical data summaries, risk factors, and management’s analysis of research and development and general and administrative expenses. Current reports on Form 8-K capture material events such as the launch and progression of the INDP-D101 clinical trial, reverse stock split implementation, private placements of convertible promissory notes and warrants, standby equity purchase agreements, preferred stock financings, and changes to the board of directors and executive leadership.
Registration statements on Form S-1 and amendments (S-1/A) outline the terms of securities offerings, including common stock, pre-funded warrants, common warrants and placement agent warrants, as well as estimated offering expenses and recent sales of unregistered securities. These filings also confirm Indaptus’ status as a smaller reporting company and non-accelerated filer and provide information on its incorporation and principal executive offices.
On Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points such as capital structure changes, potential dilution from convertible instruments and warrants, and the implications of preferred stock transactions. The platform also surfaces insider-related disclosures and board changes reported in 8-Ks, helping readers quickly identify governance developments. Real-time updates from EDGAR ensure that new Indaptus filings, from quarterly earnings reports to material event disclosures, are added promptly, while AI-generated explanations help interpret complex prospectus language, financing terms and clinical program descriptions within the filings.
Indaptus Therapeutics, Inc. reported changes to executive compensation and board composition. The company entered into salary adjustment agreements with Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, Ph.D. Effective January 15, 2026, each executive’s salary was set at $60,000 per year for the remainder of the year, paid according to the company’s standard payroll practices.
The company also disclosed that board member Anthony Maddaluna, who had previously notified the company of his intention to resign as of the next special meeting of stockholders, has rescinded that resignation. He will remain on the Board of Directors and continue to serve on the Compensation Committee and Nominating Committee.
Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company. The filing shows that he has no beneficial ownership of non-derivative or derivative securities of Indaptus as of the event date, and his position is reported as a director filing on his own behalf.
Indaptus Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed David Natan to fill the new seat. He was named a Class II director with a term running until the 2026 annual meeting of stockholders, when he will stand for election. Natan was designated by David E. Lazar under a securities purchase agreement dated December 22, 2025.
Natan brings extensive finance and public company experience, including leadership roles at multiple companies and service on other public boards and audit committees. He was also appointed to the Audit Committee, replacing Avraham Ben-Tzvi, who will remain on the board and is expected to serve as a paid consultant. The board determined that Natan qualifies as an independent director and meets Nasdaq’s heightened independence standards for audit committee service. He will participate in the company’s non-employee director compensation program.
Indaptus Therapeutics, Inc. entered into a Securities Purchase Agreement with David E. Lazar, under which he bought 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock at
The deal is paired with major governance changes: Lazar becomes Chairman and Co‑Chief Executive Officer, and Avraham Ben‑Tzvi joins the board, filling seats of two resigning directors who left without disagreements. Executive officers agreed to modified employment terms, including reduced notice periods and a mix of cash and stock settlements, and the Chief Medical Officer resigned with a cash bonus payment. New certificates of designation give the preferred stock senior liquidation preference and limited voting rights, while a voting agreement commits key executives to support board‑recommended proposals at an upcoming special stockholder meeting.
Indaptus Therapeutics (INDP) filed its Q3 2025 10‑Q, reporting a net loss of $2,975,117 for the quarter and $12,736,466 for the nine months ended September 30, 2025. Operating expenses were $2,648,487 in Q3, with R&D at $1,517,723 and G&A at $1,130,764. Cash and cash equivalents were $5,825,639 at quarter‑end.
The company states there is substantial doubt about its ability to continue as a going concern. Management believes current cash funds operations into the first quarter of 2026 and is pursuing additional financing. During 2025, Indaptus raised capital via a $20.0 million SEPA (net proceeds approximately $1.74 million to date), $5.7 million of convertible notes (automatically converted on July 27, 2025 into 501,566 shares and pre‑funded warrants), and an ATM sale of 520,000 shares for net proceeds of about $2.25 million in September.
The company effected a 1‑for‑28 reverse stock split on June 26, 2025, regaining Nasdaq bid‑price compliance. Shares outstanding were 1,641,920 as of September 30, 2025; as context, 1,751,163 were outstanding as of November 11, 2025. Indaptus continues Phase 1 development of Decoy20, including a combination study with tislelizumab, and has paused further enrollment pending additional efficacy evaluations.
Indaptus Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The company states that the full text of this earnings press release is provided as Exhibit 99.1 and is incorporated by reference. Indaptus clarifies that the information in this report, including the exhibit, is being furnished rather than filed, which limits its exposure to certain Exchange Act liabilities. The report is signed on behalf of the company by its Chief Financial Officer, Nir Sassi.
Indaptus Therapeutics, Inc. filed an amendment to its IPO registration (Form S-1/A) that discloses discrete offering-related costs and contains executed signatures from executive officers and directors dated September 3, 2025. The filing lists a FINRA filing fee of $2,806, accounting fees of $20,000 and legal fees of $70,000. The exhibit index references multiple exhibits with several marked as previously filed and at least one exhibit filed herewith. Apart from fees, exhibit identifiers and executed signatures for the CEO, CFO, Chief Scientific Officer and multiple directors, the excerpt contains no operational results, balance sheet figures, nor other financial statements.
Indaptus Therapeutics filed an S-1 to register an offering that will raise unspecified gross proceeds to fund research and development and for working capital. The company will pay the placement agent a 7.0% cash fee, a 1.0% management fee, reimburse up to $50,000 in non-accountable expenses, up to $100,000 in legal fees, and up to $15,950 in clearing expenses, and will issue placement agent warrants equal to 6.0% of the aggregate securities sold at an exercise price equal to 125% of the combined public offering price.
The offering contemplates up to 1,562,500 common warrants (split into Series A and B) and structure includes shares, pre-funded warrants and two warrants per share. Net tangible book value per share was $(2.765) as of June 30, 2025 and pro forma $3.725 after adjustments. Outstanding common shares shown: actual 604,963, pro forma 1,297,324, pro forma as adjusted 2,078,574. The filing lists standard development, regulatory, financing and listing risks and states management has broad discretion over proceeds.
Indaptus Therapeutics filed a prospectus supplement (Form 424B5) that contains standard offering sections including a prospectus summary, risk factors, forward-looking statements, use of proceeds, dividend policy, dilution, plan of distribution, legal matters, experts and incorporation of documents by reference. The supplement explicitly lists multiple clinical and commercial risks including timing and cost of an investigational new drug application and clinical trials, receipt of favorable clinical results, regulatory approval, intellectual property and licensing, development, manufacturing and commercialization, product liability and reimbursement, and capital requirements.
The document discloses a net tangible book value per share of $(2.765) as of June 30, 2025, and a pro forma net tangible book value per share of $3.725 after pro forma adjustments. It also identifies members of the board by class: Class I directors Hila Karah, Dr. Mark J. Gilbert and Robert E. Martell; Class II directors Anthony Maddaluna and William B. Hayes; and Class III directors Jeffrey A. Meckler, Michael J. Newman, Ph.D. and Dr. Roger J. Pomerantz.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
